Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G VivasEarly pregnancy care — gestational trophoblastic disease

O&G Vivas · Early pregnancy care — gestational trophoblastic disease

Gestational trophoblastic disease — structured oral station (12 minutes)

FRANZCOG oral-format station on complete hydatidiform mole: explaining the diagnosis and prognosis with rapport, suction evacuation and its cautions, hCG surveillance with contraception, the FIGO staging and score, and the single-agent versus EMA-CO treatment decision. Scored against the eight published RANZCOG oral domains.

clinical4 min readVerification in progress

Target exams

FRANZCOGMRCOGABOG
On this page
Study tools

Target exams

FRANZCOGMRCOGABOG
Prompt
You are the gynaecology registrar in the early pregnancy assessment unit. A 30-year-old G1P0 attends at 10 weeks with irregular bleeding and an hCG of 180 000 IU per litre. Ultrasound shows a complete hydatidiform mole. She is distressed and asking whether she will still be able to have children. The examiner will ask you to explain the diagnosis and prognosis, then explore your evacuation and surveillance plan, your interpretation of the hCG trend, and your approach to neoplasia if it develops.

Station format

4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual presentations; rapport with patient, support person or colleague; respect; communication skills. This station exercises clinical knowledge and the management domains heavily, but the opening probe — giving her the prognosis she asked for — sets the rapport and communication marks. [1]

Reveal the examiner script and model responsesShowHide

Opening prompt — "She is asking if she can still have children. Answer her."

Model response — the prognosis is the reassurance: [1][2]

  • Set up and listen. Sit at her level, acknowledge the distress, and confirm she has heard the word molar pregnancy before asking what she understands.
  • Name the diagnosis plainly: "This is a molar pregnancy — an abnormal fertilisation where the placenta grows into cysts instead of supporting a baby. There is no viable pregnancy here, and that is not your fault."
  • Give the prognosis she asked for: "This is one of the most curable conditions we treat. Most women need only the evacuation and follow-up blood tests, and your fertility afterwards is usually normal."
  • Then the honesty: "A small proportion go on to need chemotherapy, and even then the cure rate is extremely high. I will follow your pregnancy hormone closely afterwards so that if anything more is needed we catch it early."[1][2]

Examiner is listening for: the diagnosis in plain language, absolution, the prognostic honesty without doom, and an explicit commitment to follow-up. [2]

Probe 1 — "Talk me through the evacuation."

  • "Suction evacuation under ultrasound guidance, by an experienced operator, with a large cannula. It is the preferred method regardless of uterine size."[1][5]
  • "I would not give oxytocin until the evacuation is under way — oxytocics before suction can push trophoblast into the circulation and cause lung problems. I would not use medical induction or hysterotomy, because both spread the trophoblast."[1][6]
  • "She is Rh D negative if relevant, so she needs anti-D. And I send all the tissue for histology, because sometimes the diagnosis is only made afterwards — that is how the surveillance gets triggered."[5][6]

Probe 2 — "What happens after the evacuation?"

  • "Serial serum hCG, weekly until it is normal, then at decreasing intervals. I register her with the trophoblast centre so the follow-up does not get lost, and the evidence supports around six months of follow-up after the hCG spontaneously normalises — 98 per cent of persistent disease shows up within six months of evacuation."[2][3]
  • "Contraception throughout. A new pregnancy would reset the hormone clock and we would not be able to tell a pregnancy from recurrent disease."[2]
  • "I would tell her that if her hCG plateaus over four values across three weeks, or rises over three consecutive weekly values, or if choriocarcinoma is found on histology, that meets the FIGO criterion to start chemotherapy."[2]

Probe 3 — "Her hCG rises over three weekly values. How do you decide the treatment?"

  • "I stage and score her. Pelvic ultrasound and a chest radiograph are the basic imaging; a chest CT counts only lung lesions 1 cm or larger. If there is lung disease or suspicion of choriocarcinoma I add brain MRI and full-body imaging."[2]
  • "The FIGO anatomical stage is I for uterus only, II for genital structures, III for lung, IV for elsewhere. The WHO prognostic score has eight variables — age, antecedent pregnancy, interval, pre-treatment hCG, largest tumour size, site and number of metastases, and previous failed chemotherapy — eight in FIGO 2000, seven since the 2026 revision removed the chemotherapy row."[2][7]
  • "Score 6 or below is low risk — single-agent methotrexate with folinic acid or actinomycin-D. Score 7 or above is high risk — EMA-CO. The two are written together, for example Stage I:4."[2][4]

Probe 4 — "She asks what happens to her fertility with chemotherapy."

  • "Single-agent methotrexate does not impair fertility, and most women resume normal cycles. EMA-CO carries a small risk of earlier menopause because of the etoposide, but fertility is generally preserved and subsequent pregnancies are encouraged."[2]
  • "In the next pregnancy she has an early ultrasound, and an hCG six weeks after the end of any pregnancy, whatever its outcome, because the recurrence risk is around 1 per cent."[5][6][8]

Probe 5 — "What if the hCG stays positive but her urine test is negative?"

  • "That is phantom hCG — heterophile antibodies holding the hormone in the serum but not the urine. I confirm with a urine pregnancy test and serial serum dilution before I ever give chemotherapy, because treating a false positive is an avoidable harm."[2][5]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References8ShowHide
  1. [1]Seckl MJ, Sebire NJ, Berkowitz RS Gestational trophoblastic disease Lancet, 2010.PMID 20673583
  2. [2]Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Braga A, Garrett A Diagnosis and management of gestational trophoblastic disease: 2025 update Int J Gynaecol Obstet, 2025.PMID 40631439
  3. [3]Sebire NJ, Foskett M, Short D, Savage P, Stewart W, Thomson M, Seckl MJ Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit BJOG, 2007.PMID 17516969
  4. [4]McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, Newlands ES Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000 J Clin Oncol, 2002.PMID 11919242
  5. [5]Soper JT Gestational Trophoblastic Disease: Current Evaluation and Management Obstet Gynecol, 2021.PMID 33416290
  6. [6]RANZCOG Management of gestational trophoblastic disease RANZCOG Clinical Guideline C-Gyn 31, 2017.Source
  7. [7]Ngan HYS, Seckl MJ, Horowitz N, Cheung ANY, Braga A, Sekharan PK, Fridsten S, Garrett A, Yanaihara N, Wilailak S, Schmalfeldt B FIGO staging for gestational trophoblastic neoplasia: 2026 Int J Gynaecol Obstet, 2026.PMID 42473063
  8. [8]Sebire NJ Recurrent GTD and GTD coexisting with normal twin pregnancy Best Pract Res Clin Obstet Gynaecol, 2021.PMID 33451920
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousPregestational diabetes — structured oral station (12 minutes)Antenatal care — maternal medicineNextGestational trophoblastic neoplasia — structured oral station (12 minutes)Gynaecological oncology — gestational trophoblastic disease